Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development.

Détails

ID Serval
serval:BIB_3F4FA7C039DB
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development.
Périodique
Cancer Treatment Reviews
Auteur(s)
Stahel R., Bogaerts J., Ciardiello F., de Ruysscher D., Dubsky P., Ducreux M., Finn S., Laurent-Puig P., Peters S., Piccart M., Smit E., Sotiriou C., Tejpar S., Van Cutsem E., Tabernero J.
ISSN
1532-1967 (Electronic)
ISSN-L
0305-7372
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
41
Numéro
2
Pages
129-135
Langue
anglais
Résumé
Despite intense efforts, the socioeconomic burden of cancer remains unacceptably high and treatment advances for many common cancers have been limited, suggesting a need for a new approach to drug development. One issue central to this lack of progress is the heterogeneity and genetic complexity of many tumours. This results in considerable variability in therapeutic response and requires knowledge of the molecular profile of the tumour to guide appropriate treatment selection for individual patients. While recent advances in the molecular characterisation of different cancer types have the potential to transform cancer treatment through precision medicine, such an approach presents a major economic challenge for drug development, since novel targeted agents may only be suitable for a small cohort of patients. Identifying the patients who would benefit from individual therapies and recruiting sufficient numbers of patients with particular cancer subtypes into clinical trials is challenging, and will require collaborative efforts from research groups and industry in order to accelerate progress. A number of molecular screening platforms have already been initiated across Europe, and it is hoped that these networks, along with future collaborations, will benefit not only patients but also society through cost reductions as a result of more efficient use of resources. This review discusses how current developments in translational oncology may be applied in clinical practice in the future, assesses current programmes for the molecular characterisation of cancer and describes possible collaborative approaches designed to maximise the benefits of translational science for patients with cancer.
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/03/2015 21:36
Dernière modification de la notice
20/08/2019 14:36
Données d'usage